# Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer

> **NCT04534218** · PHASE2 · COMPLETED · sponsor: **Centre Hospitalier Universitaire de Besancon** · enrollment: 49 (actual)

## Conditions studied

- Colo-rectal Cancer
- Metastatic Cancer

## Interventions

- **DRUG:** Regorafenib
- **DRUG:** Cyclophosphamide
- **DRUG:** Capecitabine
- **DRUG:** Aspirin

## Key facts

- **NCT ID:** NCT04534218
- **Lead sponsor:** Centre Hospitalier Universitaire de Besancon
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-16
- **Primary completion:** 2023-12-13
- **Final completion:** 2023-12-13
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2024-12-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04534218

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04534218, "Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT04534218. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*